Vireo Growth (VREOF) Non-Current Assets (2020 - 2026)
Vireo Growth's (VREOF) quarterly Non-Current Assets came in at $670.5 million in Q1 2026, up 1279.27% year-on-year from $48.6 million in Q1 2025, and up 30.93% quarter-over-quarter from $512.1 million in Q4 2025.
Vireo Growth (VREOF) Non-Current Assets (2020 - 2026) Analysis & Trends
Vireo Growth has disclosed Non-Current Assets across 7 years of filings, most recently posting $670.5 million for Q1 2026.
- Non-Current Assets for Q1 2026 came in at $670.5 million, up 1279.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 884.23% YoY), and the FY2025 annual result was $512.1 million, up 956.06% from the prior year.
- Non-Current Assets came in at $670.5 million for Q1 2026 at Vireo Growth, up from $512.1 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $670.5 million in Q1 2026 to a low of $34.4 million in Q4 2023.
- The 5-year median for Non-Current Assets is $49.9 million (2024), against an average of $162.8 million.
- Across the five-year window, Non-Current Assets tumbled 69.4% in 2023 and soared 1279.27% in 2026, its largest moves.
- Vireo Growth's Non-Current Assets stood at $112.4 million in 2022, then sank by 69.39% to $34.4 million in 2023, then soared by 40.92% to $48.5 million in 2024, then soared by 956.06% to $512.1 million in 2025, then surged by 30.93% to $670.5 million in 2026.
- The last three Non-Current Assets figures came in at $670.5 million (Q1 2026), $512.1 million (Q4 2025), and $371.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 26.33 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 8.68 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 3.84 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 2.47 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 9.64 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.90 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.22 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.40 Bn |
| 10 | Vireo Growth | - | - | 59.30 Mn | 670.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 670.50 Mn |
| Dec 31, 2025 | 512.10 Mn |
| Sep 30, 2025 | 370.95 Mn |
| Jun 30, 2025 | 346.55 Mn |
| Mar 31, 2025 | 48.61 Mn |
| Dec 31, 2024 | 48.49 Mn |
| Sep 30, 2024 | 49.90 Mn |
| Jun 30, 2024 | 46.05 Mn |
| Mar 31, 2024 | 43.71 Mn |
| Dec 31, 2023 | 34.41 Mn |
| Sep 30, 2023 | 36.56 Mn |
| Jun 30, 2023 | 39.58 Mn |
| Mar 31, 2023 | 43.08 Mn |
| Dec 31, 2022 | 112.43 Mn |
| Sep 30, 2022 | 119.46 Mn |
| Jun 30, 2022 | 122.43 Mn |
| Mar 31, 2022 | 121.98 Mn |
| Dec 31, 2021 | 125.33 Mn |
| Sep 30, 2021 | 119.41 Mn |
| Jun 30, 2021 | 70.71 Mn |